Loading stock data…
ENVB
$3.99+0.04 (+1.01%)
Market ClosedLast close May 1
Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Enveric Biosciences, Inc. in the Healthcare sector is trading at $3.99. The stock is currently near its 52-week low of $1.71, remaining 39.5% below its 200-day moving average. Technical signals show neutral RSI of 66 and bullish MACD crossover, explaining why ENVB maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Overbought levels (RSI 66) — risk of consolidation or pullback
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$3.99
Potential Upside
5%
Whystock Fair Value$4.19
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. The company offers product candidates are EB-002, an active metabolite of...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$7.15M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.33
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-1242.82%
Volume
Today's trading volume
598,294
Recent News
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Key Takeaways; Cannabis Sector Organigram Secured C$65.2 Million Strategic Investment from British American Tobacco After the Company Agreed to Acquire Sanity Group Canopy Growth Secured Shareholder Backing for MTL Cannabis Acquisition Green Thumb Expanded Credit Facility with Additional $50 Million Key Takeaways; Psychedelic Sector Enveric Reported New EB‑003 Data Highlighting Non-Hallucinogenic Neuroplastogen Strategy Compass Pathways […]
Enveric Biosciences reports EB-003 receptor engagement assay data
Enveric Biosciences (ENVB) announced new mechanistic data demonstrating that its lead candidate, EB-003, activates both Gq- and ss-arrestin-mediated signaling downstream of the 5-HT2A receptor. Multiple independent, peer-reviewed studies have previously shown that selective activation of 5-HT2A receptor, by either Gq-biased or ss-arrestin-biased agonists, can independently produce antidepressant- and anxiolytic-like effects in preclinical models, suggesting that therapeutic benefit can arise fro
Enveric Biosciences announces issuance of U.S. patent
Enveric Biosciences (ENVB) announced the issuance of U.S. Patent No. 12,492,179 entitled, “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives” with claims to compositions and methods of treatment for novel molecules with the potential to be developed for mental health disorders. The ‘179 patent expands the protection of Enveric’s pipeline of potentially neuroplastogenic and non-hallucinogenic molecules. Claim 70% Off TipRanks This Holiday SeasonUnlock hedge fund-level data and power
AbbVie's Bretisilocin Hit With Enveric IP Claim
Shares pop 20% as legal fight looms
Enveric Biosciences hires Fish & Richardson to defend patent tied to AbbVie deal
Investing.com -- Enveric Biosciences (NASDAQ: ENVB) has hired prominent intellectual property law firm Fish and Richardson P.C. to contest a Post-Grant Review (PGR) petition filed by Gilgamesh Pharmaceuticals, which earlier this year agreed to be acquired by AbbVie for up to $1.2 billion, Investing.com has learned.